Literature DB >> 2794371

Exogenous estrogen effect on lipid/lipoprotein cholesterol in transsexual males.

M D Damewood1, J J Bellantoni, P S Bachorik, A W Kimball, J A Rock.   

Abstract

Lipid/lipoprotein cholesterol values and sex-hormone-binding globulin levels were determined in 40 transsexual males aged 20-38, 20 castrated and 20 non-castrated, taking conjugated estrogens to induce female characteristics. Variables controlled included dose of estrogen, age, weight, smoking, alcohol intake, exercise and diet history. Transsexual males on estrogens had significantly higher mean (+/- SE) HDL cholesterol levels (69.0 +/- 7.1 mg/dl) respectively, for castrated males and (53.8 +/- 6.2 mg/dl) for non-castrated males, respectively compared to normal control males not on hormonal therapy (41.5 +/- 5.4) (p less than 0.001), regardless of dose of estrogen received. The total cholesterol/HDL ratio was 3.31-4.05 in transsexual males on estrogens compared to 5.03 for normal males (p less than 0.001). Transsexual males had mean SHBG levels in the female range (63.4 to 71.8 nmol/ml), significantly higher than controls (26.7 nmol/ml) (p less than 0.001). SHBG levels were correlated with estrogen use, dose and HDL cholesterol levels. We conclude that exogenous estrogens administered to transsexual males results in a female pattern of lipid/lipoprotein cholesterol and SHBG concentration. The decreased total cholesterol/HDL ratio may imply a lower atherogenic potential and a lessened cardiovascular risk in males who take estrogens.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2794371     DOI: 10.1007/BF03350728

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  21 in total

1.  Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men.

Authors:  G G Rhoads; C L Gulbrandsen; A Kagan
Journal:  N Engl J Med       Date:  1976-02-05       Impact factor: 91.245

2.  A filter assay for the sex steroid binding protein (SBP) of human serum.

Authors:  K E Mickelson; P H Petra
Journal:  FEBS Lett       Date:  1974-08-15       Impact factor: 4.124

3.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

4.  Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease.

Authors:  G J Miller; N E Miller
Journal:  Lancet       Date:  1975-01-04       Impact factor: 79.321

5.  Lipoprotein-cholesterol distributions in selected North American populations: the lipid research clinics program prevalence study.

Authors:  G Heiss; I Tamir; C E Davis; H A Tyroler; B M Rifkand; G Schonfeld; D Jacobs; I D Frantz
Journal:  Circulation       Date:  1980-02       Impact factor: 29.690

6.  High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study.

Authors:  T Gordon; W P Castelli; M C Hjortland; W B Kannel; T R Dawber
Journal:  Am J Med       Date:  1977-05       Impact factor: 4.965

7.  Relationship of plasma HDL-cholesterol to testosterone, estradiol, and sex-hormone-binding globulin levels in men and women.

Authors:  J Semmens; I Rouse; L J Beilin; J R Masarei
Journal:  Metabolism       Date:  1983-05       Impact factor: 8.694

8.  Androgen parameters and their correlation with body weight in one hundred thirty-eight women thought to have hyperandrogenism.

Authors:  R A Wild; E S Umstot; R N Andersen; G B Ranney; J R Givens
Journal:  Am J Obstet Gynecol       Date:  1983-07-15       Impact factor: 8.661

9.  Plasma apolipoprotein A-1 absence associated with a marked reduction of high density lipoproteins and premature coronary artery disease.

Authors:  E J Schaefer; W H Heaton; M G Wetzel; H B Brewer
Journal:  Arteriosclerosis       Date:  1982 Jan-Feb

10.  Suppression of plasma testosterone leads to an increase in serum total and high density lipoprotein cholesterol and apoproteins A-I and B.

Authors:  R B Goldberg; D Rabin; A N Alexander; G C Doelle; G S Getz
Journal:  J Clin Endocrinol Metab       Date:  1985-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.